参考文献/References:
[1] Marra MP, Lima JAC, Iliceto S. MRI in acute myocardial infarction[J]. Eur Heart J,2011,32(3):284-293.
[2] Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis[J]. J Am Coll Cardiol,2013,59(19):1719-1728.
[3] Heydari B, Jerosch M. Assessment of myocardial ischemia with cardiovascular magnetic resonance[J].Prog Cardiovasc Dis,2011,54(3):191-203.
[4] Grover S, Srinivasan G, Selvanayagam JB. Evaluation of myocardial viability with cardiac magnetic resonance imaging[J]. Prog Cardiovasc Dis,2011, 54(3):204-214.
[5] Thouet T, Schnackenburg B, Kokocinski T, et al. Visualization of chronic myocardial infarction using the intravascular contrast agent MS-325(gadofosveset)in patients[J]. Sci World J,2012,2012(1):236401.
[6] Schuster A, Paul M, Bettencourt N,et al. Myocardial feature tracking reduces observer-dependence in low-dose dobutamine stress cardiovascular magnetic resonance[J]. PLoS One,2015,10(4):e0122858.
[7] Wellnhofer E, Olariu A, Klein C,et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery[J]. Circulation,2004,109(18):2172-2174.
[8] Weinsaft JW,Klem I,Judd RM.MRI for the assessment of myocardial viability[J].Magn Reson Imaging Clin N Am,2007,15(1):505-525.
[9] Tomlinson DR,Becher H,Selvanayagam JB.Assessment of myocardial viability:comparison of echocardiography versus cardiac magnetic resonance imaging in the currentera[ J].Heart Lung Circ,2008,17(3):173-185.
[10] Ogawa M,Doi k,Fukumoto A,et al.Reverse-remodeling after coronary artery bypass grafting in ischemic cardiomyopathy:assessment of myocardial viability by delayed-enhanced magnetic resonance imaging can help cardiac surgeons[J].Interact Cardiovasc Thorac Surg,2007,6(5):673-675.
[11] Karamitsos TD, Leccisotti L, Arnold JR,et al.Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease:insights from cardiovascular magnetic resonance and position emission tomography[J].Circ cardiovasc Imaging,2010,1(1):32-40.
[12] Glaveckaite S, Valeviciene N, Palionis D, et al. Prediction of long-term segmental and global functional recovery of hibernating myocardium after revascularisation based on low dose dobutamine and late gadolinium enhancement cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2014,16(1):83.
[13] Baer FM, Voth E, LaRosee K, et al. Comparison of dobutamine transesophageal echocardiography and dobutamine magnetic resonance imaging for detection of residual myocardial viability[J]. Am J Cardiol,1996,78(4):415-419.
[14] Charoenpanichkit C, Hundley WG. The 20 year evolution of dobutamine stress cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2010, 12(5):652-653.
[15] 贺毅,张兆琪,郭淼,等.比较小剂量多巴酚丁胺负荷磁共振评价陈旧性心肌梗死和心肌活性的联系[J].心肺血管病杂志,2010,1:19-22.
[16] Hamon M, Fau G, Nee G, et al.Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease[J]. J Cardiovasc Magn Reson,2010,12(1):29.
[17] Romero J, Xue X, Gonzalez W, et al. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease[J]. JACC Cardiovasc Imaging,2012,5(5):494-508.
[18] Scott AE, Semple SI, Redpath TW, et al. Low-dose dobutamine adds incremental value to late gadolinium enhancement cardiac magnetic resonance in the prediction of adverse remodelling following acute myocardial infarction[J]. Eur Heart J Cardiovasc Imaging,2013,14(9):906-913.
[19] Kaandorp TAM, Bax JJ, Schuijf JD, et al. Head-to-head comparison between contrast-enhanced magnetic resonance imaging and dobutamine magnetic resonance imaging in men with ischemic cardiomyopathy[J]. Am J Cardiol, 2004,93(12):1461-1464.
[20] Fiocchi F, Sgura F,di Girolamo A, et al. Chronic total coronary occlusion in patients with intermediate viability:value of low-dose dobutamine and contrast-enhanced 3-T MRI in predicting functional recovery in patients undergoing percutaneous revascularisation with drug-eluting stent[J]. Radiol Med,2009,114(5):692-704.
[21] Romero J, Kahan J, Kelesidis I,et al. CMR imaging for the evaluation of myocardial stunning after acute myocardial infarction:a meta-analysis of prospective trials[J]. Eur Heart J Cardiovasc Imaging,2013,14(11):1080-1091.
[22] Gebker R, Jahnke C, Manka R, et al. The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease[J]. J Cardiovasc Magn Reson, 2011,13(2):46.
相似文献/References:
[1]翟恒博,综述,刘俊,等.缺血性心脏病再认识[J].心血管病学进展,2016,(4):395.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.018]
ZHAI Hengbo,LIU Jun.Rethinking of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):395.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.018]
[2]施国荣 刘婷婷 田欣 祝自新 郑文荣 王宇峰 孙芳玲 王文.Eph/ephrin信号通路在缺血性心脏病中血管生成中的研究进展[J].心血管病学进展,2021,(2):158.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.016]
Shi Guorong,Liu Tingting,Tian Xin,et al.Research Progress of Eph/ephrin Signaling Pathway in Angiogenesis of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2021,(3):158.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.016]
[3]肖轶 余国龙.不同干细胞来源的外泌体在缺血性心脏病中的促血管新生作用[J].心血管病学进展,2022,(4):293.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.002]
XIAO Yi,YU Guolong?/html>.Application of Exosomes Derived from Various Stem Cells?n Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(3):293.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.002]
[4]琚敏 汪蕾 宋雷 方纬.心脏交感神经显像的临床应用和研究进展[J].心血管病学进展,2023,(1):16.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.005]
JU Min,WANG Lei,SONG Lei,et al.Clinical Application and Research Progress of Cardiac Sympathetic Imaging[J].Advances in Cardiovascular Diseases,2023,(3):16.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.005]
[5]庞自豪 贾青青 韩博文 张莉.药物调控哺乳动物雷帕霉素靶蛋白相关信号通路在缺血性心脏病中的研究进展[J].心血管病学进展,2024,(4):326.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.009]
PANG Zihao,JIA Qingqing,HAN Bowen,et al.Research Progress In Drug Regulated mTOR Related Signaling Pathway?span>In Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2024,(3):326.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.009]
[6]闻雪松 刘焕.β受体阻滞剂在心血管疾病中的研究及应用进展[J].心血管病学进展,2024,(7):632.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.013]
WEN Xuesong,LIU Huan.Role of -Blockers in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(3):632.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.013]